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A B S T R A C T
Background
Raised intraocular pressure is a risk factor for glaucoma. One treatment option is glaucoma drainage surgery (trabeculectomy). An-
timetabolites are used during surgery to reduce postoperative scarring during wound healing. Two agents in common use are mitomycin
C (MMC) and 5-Fluorouracil (5-FU).
Objectives
To assess the effects of MMC compared to 5-FU as an antimetabolite adjunct in trabeculectomy surgery.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015 Issue 9), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to October
2015), EMBASE (January 1980 toOctober 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (Jan-
uary 1982 to October 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).
We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2
October 2015.
Selection criteria
We included randomised controlled trials where wound healing had been modified with MMC compared to 5-FU.
Data collection and analysis
Two review authors independently selected trials and collected data. The primary outcome was failure of a functioning trabeculectomy
one year after surgery. Secondary outcomes included mean intraocular pressure at one year.We considered three subgroups: high risk of
trabeculectomy failure (people with previous glaucoma surgery, extracapsular cataract surgery, African origin and people with secondary
glaucoma or congenital glaucoma); medium risk of trabeculectomy failure (people undergoing trabeculectomy with extracapsular
cataract surgery) and low risk of trabeculectomy failure (people who have received no previous surgical eye intervention).
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Main results
We identified 11 trials that enrolled 687 eyes of 679 participants. The studies were conducted in the United States, Europe, Asia and
Africa. Five studies enrolled participants at low risk of trabeculectomy failure, five studies enrolled participants at high risk of failure,
and one study enrolled people with both high and low risk of failure. None of the included trials enrolled participants with combined
trabeculectomy/cataract surgery.
We considered one study to be at low risk of bias in all domains, six studies to be at high risk of bias in one or more domains, and the
remaining four studies to be at an unclear risk of bias in all domains.
The risk of failure of trabeculectomy at one year after surgery was less in those participants who receivedMMC compared to those who
received 5-FU, however the confidence intervals were wide and are compatible with no effect (risk ratio (RR) 0.54, 95% confidence
interval (CI) 0.30 to 1.00; studies = 11; I2 = 40%). There was no evidence for any difference between groups at high and low risk of
failure (test for subgroup differences P = 0.69).
On average, people treated with MMC had lower intraocular pressure at one year (mean difference (MD) -3.05 mmHg, 95% CI -4.60
to -1.50), but the studies were inconsistent (I2 = 52%). The size of the effect was greater in the high-risk group (MD -4.18 mmHg,
95% CI -6.73 to -1.64) compared to the low-risk group (MD -1.72 mmHg, 95% CI -3.28 to -0.16), but again the test for interaction
was not statistically significant (P = 0.11).
Similar proportions of eyes treated with MMC lost 2 or more lines of visual acuity one year after surgery compared to 5-FU, but the
confidence intervals were wide (RR 1.05, 95% CI 0.54 to 2.06).
Adverse events occurred relatively rarely, and estimates of effectwere generally imprecise. There was some evidence for less epitheliopathy
in the MMC group (RR 0.23, 95% CI 0.11 to 0.47) and less hyphaema in the MMC group (RR 0.62, 95% CI 0.42 to 0.91).
None of the studies reported quality of life.
Overall, we graded the quality of the evidence as low largely because of risk of bias in the included studies and imprecision in the
estimate of effect.
Authors’ conclusions
We found low-quality evidence that MMCmay be more effective in achieving long-term lower intraocular pressure than 5-FU. Further
comparative research on MMC and 5-FU is needed to enhance reliability and validity of the results shown in this review. Furthermore,
the development of new agents that control postoperative scar tissue formation without side effects would be valuable and is justified
by the results of this review.
P L A I N L A N G U A G E S U M M A R Y
Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery
Review question
DoesmitomycinC (MMC) offer any advantage in comparison to 5-Fluorouracil (5-FU) as the antimetabolite used to augment glaucoma
surgery (trabeculectomy)? Does MMC help to achieve lower rates of trabeculectomy failure than 5-FU at one year postoperatively?
Background
Raised intraocular pressure is a risk factor for glaucoma. One treatment option is glaucoma drainage surgery (trabeculectomy) to help
lower intraocular pressure. Antimetabolites are medicines used during surgery to help reduce scarring after surgery during wound
healing. If scarring occurs it can lead to treatment failure because the drainage channel no longer works. Two agents in common use
are MMC and 5-FU.
Search date
The evidence is up to date to October 2015.
Study characteristics
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We included 11 randomised controlled trials conducted in the United States, Europe, Asia and Africa in this review. In total, 687 eyes
of 679 participants underwent routine trabeculectomy for glaucoma control. Some participants were at a higher risk of failure than
others, for example if they had had previous glaucoma surgery, were of African origin, or if they had secondary glaucoma. Five studies
enrolled participants at low risk of trabeculectomy failure, five studies enrolled participants at high risk of failure, and one study enrolled
people with both high and low risk of failure. None of the included trials enrolled participants with combined trabeculectomy/cataract
surgery.
Key results
Our review showed that the risk of failure of trabeculectomy at one year after surgery was slightly less in those participants treated with
MMC compared to 5-FU. All of the included randomised controlled trials contributed to this result, with a mixed study population
of high- and low-risk participants and varied methodology of antimetabolite application. We did not detect any significant differences
between the subgroups of participants at low and high risk of failure, but the power of this analysis was low.
We identified no difference between the visual outcomes of the group that received MMC and the group that received 5-FU at one
year postoperatively nor in the number of drops used postoperatively. However, we found evidence to suggest that MMC was more
effective at lowering intraocular pressure than 5-FU in both high- and low-risk participants, achieving a lower mean intraocular pressure
postoperatively than in those who were treated with 5-FU at one year. This effect seemed to be greater in the high-risk populations.
Evaluating the overall complications across all studies revealed a slight favour toward using MMC, particularly with the incidence of
epitheliopathy and hyphaema. There was a trend towards bleb leaks, wound leaks, late hypotony and cataract formation in the MMC-
treated group.
None of the studies reported quality of life.
Quality of the evidence
We graded the quality of the evidence as low, mostly due to the risk of bias in the included studies. One bias we commonly encountered
came from the different techniques of antimetabolite administration, making it difficult to conceal which medicine was being used.
Furthermore, most studies only had a few complications to report, which meant that there were low numbers overall to include in the
analysis of complications.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
MMC compared to 5-FU for wound healing in glaucoma surgery
Patient or population: wound healing in glaucoma surgery
Settings:
Intervention: MMC
Comparison: 5-FU
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants/eyes
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
5-FU MMC
Failure of functioning tra-
beculectomy at 1 year
Study population Low-risk population RR
0.65 (95% CI 0.19 to 2.
20)
High-risk population RR
0.49 (95% CI 0.22 to 1.
08)
634
(11 RCTs: 6 including
low-risk population and 5
including high-risk popu-
lation)
⊕⊕©©
LOW 1,2
Low-risk population: 74
per 1000
High-risk population: 272
per 1000
Low-risk population: 50
per 1000
High-risk population: 137
per 1000
Intraocular pressure at 1
year
The mean intraocular
pressure at 1 year ranged
across 5-FU groups
Low-risk population: 10.
9 to 14.3 mmHg
High-risk population: 14.
8 to 16.3 mmHg
The mean intraocular
pressure at 1 year in the
MMC groups had a range
of values
Low-risk population: 9.9
to 11.6 mmHg
High-risk population: 8.6
to 13.7 mmHg
- 386
(7 RCTs: 3 including low-
risk population and 4 in-
cluding high-risk popula-
tion)
⊕⊕©©
LOW 1,3
Loss of 2 or more lines of
Snellen visual acuity at 1
year
Study population Low-risk population RR
2.00 (95% CI 0.53 to 7.
59)
High-risk population RR
0.81 (95% CI 0.36 to 1.
80)
328
(5 RCTs: 2 including low-
risk population and 3 in-
cluding high-risk popula-
tion)
⊕⊕©©
LOW 2,4
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Low-risk population: 47
per 1000
High-risk population: 115
per 1000
Low-risk population: 94
per 1000
High-risk population: 96
per 1000
Postoperative complica-
tions: late hypotony
Study population RR 1.37 (95% CI 0.41 to
4.63)
211
(4 RCTs)
⊕⊕©©
LOW 2,4
37 per 1000 59 per 1000
Postoperative complica-
tions: choroidal detach-
ment
Study population RR 0.86 (95% CI 0.45 to
1.63)
494
(8 RCTs)
⊕⊕©©
LOW 1,2
68 per 1000 70 per 1000
Postoperative complica-
tions: endophthalmitis
Study population RR 3.89 (95% CI 0.44 to
34.57)
315
(4 RCTs)
⊕⊕©©
LOW 1,2
0 per 1000 19 per 1000
Quality of life at 1 year Not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
5-FU: 5-Fluorouracil; CI: confidence interval; MMC: mitomycin C; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded for risk of bias: only one study at low risk of bias in all domains
2Downgraded for imprecision: wide confidence intervals
3Downgraded for inconsistency: I2 = 60%
4Downgraded for risk of bias: no study at low risk of bias in all domains
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B A C K G R O U N D
Description of the condition
Glaucoma is a chronic, progressive optic neuropathy characterised
by a progressive loss of ganglion cells that leads to a characteristic
visual function loss. Intraocular pressure (IOP) is often considered
to be a major risk factor for glaucoma, and it is the only factor that
can be modified to try to change the course of the condition. The
publication of a series of randomised controlled trials (RCTs) has
established the evidence for treating glaucoma with IOP reduction
(AGIS 1998; CNTGS 1998; Heijl 2002; Kass 2002; Maier 2005;
Vass 2007).
Glaucoma drainage surgery remains an important treatment op-
tion for the control of IOP despite the addition of several new
IOP-lowering drugs. Some evidence suggests that trabeculectomy
is more effective than either medicine or laser treatment alterna-
tives (Migdal 1994). However, a Cochrane systematic review from
2012 found that visual field deterioration up to five years is not
significantly different whether treatment is initiated with medica-
tion or trabeculectomy (Burr 2012).
Optimum success rates are achieved when the eye has been ex-
posed to no previous interventions, either surgical or medical, al-
though this is not the usual situation in high-income countries.
Risk factors for trabeculectomy failure are thought to be those
that increase the scarring response and include previous exposure
to topical medication, previous surgical manipulation of the con-
junctiva or other injury, young age, African origin, a history of
uveitis and neovascular glaucoma (EGS 2003).
Presentation and diagnosis
The diagnosis of glaucoma is made by the identification of a pro-
gressive optic neuropathy or a characteristic visual field defect.
There are subgroups of glaucoma, primary open angle glaucoma
being most common in European and African populations. A per-
son with primary open angle glaucoma is often unaware of any
symptoms until the late stages of the disease, making early diag-
nosis essential.
Description of the intervention
Treatment is usually initiated with topical treatment, and surgical
options are considered if topical treatment fails to prevent progres-
sion of the disease. The trabeculectomy produces a guarded fis-
tula between the anterior chamber and the subconjunctival space.
There have been numerous modifications since its first description
(Cairns 1968), including the use of antimetabolites to reduce fi-
broblast activity and postoperative scarring at the site of the scleral
flap and the subconjunctival space.
How the intervention might work
Once trabeculectomy has been selected, the treatment decisions
are whether to augment the surgery with antiscarring agents such
as antimetabolites. Antimetabolites are applied to the surgical site
to inhibit fibroblast activity and reduce postoperative scarring; the
two agents commonly in use are mitomycin C (MMC) and 5-
Fluorouracil (5-FU). Due to reported side effects such as increased
risk of bleb leak, hypotony and endophthalmitis (DeBry 2002),
there is concern that use of these agents should be restricted to
high-risk cases only. A number of RCTs have reported the use
of MMC (Andreanos 1997; Carlson 1997; Cohen 1996; Costa
1996; Martini 1997; Robin 1997; Shin 1995; Shin 1998; Wu
1996). A Cochrane systematic review concluded that compared to
placebo, MMC reduces mean IOP at 12 months in all groups of
participants (Wilkins 2010). Apart from increase in cataract for-
mation, therewas insufficient power to detect any increase in other
serious side effects. Postoperative 5-FU injections to augment tra-
beculectomy have also been assessed with RCTs (FFSSG 1989;
Goldenfeld 1994; Ophir 1992; Ruderman 1987), and also confer
an improvement in IOP control at one year compared to placebo
(Green 2014). Clinically, MMC and 5-FU can be applied intra-
operatively on a sponge placed for one to five minutes between the
conjunctiva and sclera at the start of the operation. Alternatively,
5-FU may be given as one or more postoperative subconjunctival
injections. There is marked variation in the concentrations of both
drugs used, the time of intraoperative application and the position
and volume of postoperative injections.
Why it is important to do this review
The results of twoCochrane reviews comparingMMC, inWilkins
2010, and 5-FU, in Green 2014, to placebo suggest a similar
effect for the two agents in inhibiting scarring after trabeculectomy.
However, there is no direct comparative evidence to influence
which antimetabolite a surgeon should choose. The purpose of
this review was to systematically summarise the RCTs in which
MMC was compared to 5-FU in an attempt to clearly identify
treatment benefits of one agent over the other.
O B J E C T I V E S
To assess the effects of MMC compared to 5-FU as an antimetabo-
lite adjunct in trabeculectomy surgery.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included RCTs where wound healing had been modified with
one of the antimetabolites in one group of people undergoing
trabeculectomy, compared to the other antimetabolite in the other
group.
Types of participants
There were three separate subgroup populations:
• High risk of trabeculectomy failure: people with previous
glaucoma or extracapsular cataract surgery, people of African
origin and people with secondary glaucoma or congenital
glaucoma.
• Medium risk of trabeculectomy failure: (combined surgery)
people undergoing trabeculectomy with extracapsular cataract
surgery.
• Low risk of trabeculectomy failure: (primary
trabeculectomy): people who have received no previous surgical
eye intervention. People who underwent previous laser
procedures may be included in this group.
For the purpose of this review, there were no restrictions regarding
age or gender.
Types of interventions
We included the following interventions:
1. Use of intraoperative MMC versus intraoperative 5-FU.
2. Use of intraoperative MMC versus postoperative 5-FU.
3. Use of intraoperative MMC versus intraoperative and
postoperative 5-FU.
4. Use of intraoperative MMC and postoperative MMC
versus intraoperative and postoperative 5-FU.
Types of outcome measures
Primary outcomes
The primary outcome was failure of a functioning trabeculectomy
at one year from surgery (dichotomous).
We used the following definitions:
• Success: adequate pressure control (< 22 mmHg) without
additional treatment.
• Failure: need for repeat filtration surgery or uncontrolled
IOP (= or > 22 mmHg).
Secondary outcomes
• Survival analysis (time to event) for the previously given
definition of failure
• Mean IOP for each group at one year from surgery
• Quality-of-life measures
• Economic data
Adverse outcomes
Adverse events in either group with reference to choroidal detach-
ment, hypotony and late endophthalmitis were reported. Adverse
events were reported at any time during the follow-up period.
We used the following definitions:
• Bleb leakage: presence of a positive Seidel test (visible
aqueous flow with the tear film stained with fluorescein).
• Hypotony: IOP below 5 mmHg and/or associated with
complications such as macular oedema and sight loss or
choroidal detachments.
• Endophthalmitis: an infection of the globe contents that
even with prompt aggressive treatment results in substantial loss
of visual function.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2015 Issue 9), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to October 2015), EMBASE (January 1980 to October
2015), Latin American and Caribbean Health Sciences Litera-
ture Database (LILACS) (January 1982 to October 2015), the
ISRCTN registry (www.isrctn.com/editAdvancedSearch), Clini-
calTrials.gov (www.clinicaltrials.gov) and theWorld Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 2 October 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), ISRCTN (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the ICTRP (Appendix 7).
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials.We contacted investigators as necessary to identify
additional published and unpublished studies.
Data collection and analysis
Selection of studies
Three review authors (JC/EC/JE) independently reviewed the ti-
tles and abstracts resulting from the searches. We obtained full
copies of any report referring to possibly or definitely relevant trials
and assessed them according to the definitions in the Criteria for
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considering studies for this review section. We assessed only trials
meeting these predefined criteria for methodological quality. We
resolved any disagreements by discussion.
Data extraction and management
Three review authors (JC/EC/JE) independently extracted data
with relation to the outcome measures outlined above. We re-
solved discrepancies by discussion. One review author entered the
data into Review Manager (RevMan 2014), and the other review
authors checked the data entry.
Assessment of risk of bias in included studies
Three review authors (JC/EC/JE) independently assessed risk of
bias according to methods set out in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We considered six domains: random sequence generation, alloca-
tion concealment, masking, incomplete outcome data, selective
reporting and any other identified bias. We graded each domain
as low risk of bias, high risk of bias, or unclear risk of bias. For ex-
ample, in allocation concealment the grading was low risk if there
was central randomisation of subjects, high risk if there was simple
alternating methods used to allocate subjects and unclear if there
was no real qualifying statement. We resolved disagreements by
discussion. Review authors were not masked to trial details during
the assessment. We excluded trials scoring ’high risk’ on allocation
concealment. In cases where missing or confusing data did not
permit a clear grading of the trial, we contacted the study authors
in order to obtain further information.
Measures of treatment effect
Wemeasured the effect of dichotomous data by risk ratio; contin-
uous data by difference in means; and time to event data by hazard
ratio.
Unit of analysis issues
All studies were parallel-group RCTs. In the majority of studies,
one eye per person was enrolled, and therefore there were no unit
of analysis issues. In Lamping 1995, WuDunn 2002 and Xinyu
2001, both eyes of some participants were enrolled, but in most
cases this was less than 10%, and overall less than 5% of the data
would be affected by this. None of the trials took into account the
potential correlation between eyes, and we have analysed the data
from the trials as reported.
Dealing with missing data
We did an available case analysis. This assumes that data are miss-
ing at random. We assessed whether this assumption was reason-
able by collecting data from each included trial on the number
of participants excluded or lost to follow-up and reasons for loss
to follow-up by treatment group, if reported. We collected this
information as part of the assessment of attrition bias.
Assessment of heterogeneity
We examined the overall characteristics of the studies, in particular
the types of participants and interventions, in order to assess the
extent to which the studies were similar enough to make pooling
study results sensible.
We looked at the forest plot of study results to see how consistent
the studies were, in particular looking at the size and direction of
effects.
We calculated I2, which is the percentage of the variability in effect
estimates that is due to heterogeneity rather than sampling error
(chance) (Higgins 2002). We considered I2 values over 50% to
indicate substantial inconsistency or heterogeneity. We also con-
sidered Chi2 P values; when the number of studies was few we
used P less than 0.1 to indicate statistical significance of the Chi2
test.
Assessment of reporting biases
We planned to do a ’funnel plot’ to investigate reporting (publica-
tion) bias, but there were not enough included trials (fewer than
10 in each meta-analysis) to make this possible.
Data synthesis
If there was inconsistency between individual study results such
that a pooled result may not have been a good summary of the
individual trial results, for example the effects were in different
directions, or I2 was greater than 50% and P less than 0.1, we did
not pool the data but did describe the pattern of the individual
study results.
If I2 was greater than 50%, but all the effect estimates were in the
same direction such that a pooled estimate would seem to have
provided a good summary of the individual trial results, we did
pool the data.
If there was inconsistency between individual study results such
that a pooled result may not have been a good summary of the
individual trial results, for example the effects were in different
directions, or I2 was greater than 50% and P less than 0.1, we did
not pool the data but did describe the pattern of the individual
study results.
If I2 was greater than 50%, but all the effect estimates were in the
same direction such that a pooled estimate would have provided a
good summary of the individual trial results, we did pool the data.
Subgroup analysis and investigation of heterogeneity
We compared the effect of intervention in a pre-planned analysis
comparing effects in groups at high and low risk of failure.
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Sensitivity analysis
We conducted sensitivity analyses to determine the impact of risk
of bias on effect size. We repeated the analyses excluding trials at
high risk of bias in one or more domains.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 446 references (Figure
1). The Trials Search Co-ordinator scanned the search results,
removed 58 duplicates and then removed 298 references that were
not relevant to the scope of the review. We screened the remaining
90 reports and discarded 69 reports as not relevant. After assessing
the reports, we identified a further two studies studies for potential
inclusion in the review (Oh 1994;Uva 1996). In total, we obtained
23 full-text reports for potential inclusion in the review. After
consideration of each report, we included a total of 13 reports
of 11 studies in the final review; see Characteristics of included
studies and excluded seven studies; see Characteristics of excluded
studies for reasons. We have categorised three studies as awaiting
assessment, two of which we are unable to source copies of the
reports and one is awaiting a response from the authors regarding
information on methods of randomisation (Liu 2015).
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Figure 1. Study flow diagram
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Included studies
Design
We included a total of 11 studies in this Cochrane Review and
summarised them in the Characteristics of included studies. All
11 studies were designed as a prospective RCTs. One study in this
review was a multicentre study (Singh 2000); the rest were single-
centre.
Setting
Four studies were based in the United States (Katz 1995; Lamping
1995; Singh 2000; WuDunn 2002), two in Italy (Sisto 2007;
Uva 1996) and the remainder in Ghana (Singh 1997), Japan
(Kitazawa 1991), China (Xinyu 2001), Israel (Zadok 1995) and
Iran (Mostafaei 2011). All research was carried out in clinical oph-
thalmic institutes.
Participants and sample sizes
In total, 687 eyes of 679 participants underwent routine tra-
beculectomy for glaucoma control. The smallest study was of 20
eyes of 20 participants (Zadok 1995), and the largest study in-
cluded 115 eyes of 103 people (WuDunn 2002). Five studies in-
cluded high-risk cases only (Katz 1995; Kitazawa 1991; Lamping
1995; Singh 1997; Sisto 2007), one study enrolled both high- and
low-risk cases (Xinyu 2001), and the participants in the remaining
five studies were low risk. Participants across the studies were a
mixture of male and female; the percentage female ranged from
19% to 67%. The average age in the studies ranged from 47 years
to 71 years, with a median average age of 62 years. One study had
a significant age difference (P = 0.01), with a mean age of 41.2 in
the MMC group and 54.2 in the 5-FU group (Kitazawa 1991).
Interventions
We have summarised the interventions in Table 1.
The majority of trials applied MMC using an intraoperative
sponge; the exception was Mostafaei 2011, where 0.02mg MMC
was applied by intraoperative subconjunctival injection. Subcon-
junctival application of MMC is not consistent with current prac-
tice (Dhingra 2009). The MMC dose given by intraoperative
sponge varied between studies:
• Two studies used 0.5 mg/ml applied for 5 minutes, in Katz
1995, or 3.5 minutes, in Singh 1997.
• Three studies used 0.4 mg/ml applied for 5 minutes
(Kitazawa 1991), 2.5 minutes (Lamping 1995), or 2 minutes
(Singh 2000).
• Five studies used 0.2 mg/ml applied for 5 minutes, in
Xinyu 2001 and Zadok 1995, or 2 minutes, in Sisto 2007, Uva
1996 and WuDunn 2002.
The method of administration of the 5-FU varied between stud-
ies: four studies used an intraoperative sponge technique similar
to that of MMC application (Singh 1997; Singh 2000; Uva 1996;
WuDunn 2002), six trials used a series of postoperative subcon-
junctival injections (Katz 1995; Kitazawa 1991; Lamping 1995;
Sisto 2007; Xinyu 2001; Zadok 1995), and one study used intra-
operative subconjunctival 5-FU 5 mg (Mostafaei 2011). All four
studies with a group receiving intraoperative sponge-applied 5-FU
used 50 mg/ml for 5 minutes, which is consistent with current
practice (Dhingra 2009).
Different dosing regimens were used for the postoperative injec-
tions.
• Four studies used 10 postoperative injections
◦ daily for 1 week, 3 times the following week (Katz
1995);
◦ each day for 1 week, every other day for the following
week (Kitazawa 1991);
◦ first 10 days (Lamping 1995);
◦ starting on day 7, 2 injections per week for 2 weeks
and then 1 injection per week for 6 weeks (Sisto 2007).
• Two studies used approximately 7 postoperative injections
◦ once daily up to 7 times in the first week after surgery
(Zadok 1995);
◦ 6 to 8 (alternate days, starting on day 3) (Xinyu 2001)
Outcomes
All of the 11 included studies stated an optimal postoperative IOP
to achieve in order to accept success: five studies used a level of
below 21 mmHg as desirable (Kitazawa 1991; Singh 1997; Singh
2000; Sisto 2007; Zadok 1995), two studies used equal to or less
than 21 mmHg (Lamping 1995; WuDunn 2002), two used equal
to or less than12mmHg (Katz 1995;Uva 1996), one used less than
21.06 mmHg (Xinyu 2001), and one study used 6 to 22 mmHg
(Mostafaei 2011). Each study group reported their findings either
as a percentage success or mean IOP.
Excluded studies
We excluded seven studies from the review: Ashworth 2003;
Dreyer 1995; Li 2001; Membrey 2000; Membrey 2001;
Rodriguez-Bermejo 1993; Oh 1994. For further details please see
Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2; Figure 3
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
The review authors individually assessed the risk of bias. If the
relative point was addressed in a study’s manuscript, then a true
assessment of ‘high’ or ‘low’ risk was carried out. If we deemed
the risk as unclear, then this indicated we could make no true
assessment because the required information was not given either
in the published manuscript or after making contact with the lead
author.
Allocation
Five studies reported adequate methods to generate a random allo-
cation sequence: Singh 1997 tossed a coin in the operating theatre
to allocate participants; Uva 1996 used a table of random num-
bers; and the remaining three studies used computer-generated
allocation sequences (Singh 2000; Sisto 2007; WuDunn 2002).
It was unclear how the allocation schedule was generated in the
remaining six studies.
Five studies reported adequate methods of allocation concealment
(Kitazawa 1991; Singh 1997; Singh 2000; Uva 1996; WuDunn
2002)
Blinding
In four of the included studies, 5-FU was administered using a
different technique to that of MMC, and no report was given
about whether or not the follow-up information was gathered
from masked assessors. We classified all these studies as high risk
of performance and detection bias (Katz 1995; Kitazawa 1991;
Lamping 1995; Xinyu 2001).
In one study, the method of 5-FU administration was the same
as for MMC, but information gathered in the follow-up period
was not from masked assessors. We therefore classified this study
as high risk (Singh 1997).
Two studies used different techniques for antimetabolite adminis-
tration but assessors were masked during the follow-up period.We
graded these two studies as low risk of performance and detection
bias for the primary outcome of this review (Sisto 2007; Zadok
1995).
Only one study used a placebo tomask allocation,whichwe graded
as at low risk of perfomance and detection bias (WuDunn 2002).
We graded the other three studies as unclear because the surgical
administration of the antimetabolites was the same, but there was
no mention of masking during follow-up (Mostafaei 2011; Singh
2000; Uva 1996).
Incomplete outcome data
Four studies did not comment on the exclusion or inclusion of
participants in their analysis (Kitazawa 1991; Mostafaei 2011;
Singh 1997; Xinyu 2001); we classified these as unclear risk. We
classified the other seven studies as low risk as participants were
clearly identified as included or not. No studies raised any concern
over their intention to include or exclude participants.
Selective reporting
Singh 1997 did not specify in the methods of the paper what
outcomes they considered, thus we cannot be certain that all the
intended outcomes were addressed; we highlighted this as high
risk. All other studies commented on all stated outcomes.
Other potential sources of bias
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The only other sources of bias identified were that of postoperative
care with regard to what other care or medications participants re-
ceived and the varied amount of 5-FU a participant would receive
with an incomplete postoperative regimen. This was highlighted
in the study by Katz 1995. Other studies had no other clear iden-
tifiable bias.
Effects of interventions
See: Summary of findings for the main comparison MMC
compared to 5-FU for wound healing in glaucoma surgery
Failure of a functioning trabeculectomy at one year from
surgery (primary outcome)
All 11 studies reported failure of a functioning trabeculectomy at
approximately one year, which was defined as IOP above (approx-
imately) 22 mmHg or more (Analysis 1.1).
The risk of failure of trabeculectomy at one year after surgery was
lower in those treated with MMC compared to 5-FU (risk ratio
(RR) 0.54, 95% confidence interval (CI) 0.30 to 1.00; studies =
11; I2 = 40%). However, the confidence intervals of the studies
were wide, and we cannot exclude important differences.
There was no evidence for any difference between groups at high
and low risk of failure (test for subgroup differences P = 0.69), but
with only a few trials in each group, the power of the analysis to
detect any differences was low.
The dose of MMC varied across the studies included in the re-
view, and consequently we performed a dose-response analysis.We
identified a trend showing that studies increasingly favoured the
use of MMC rather than 5-FU as the intraoperative exposure to
MMC increased (Analysis 1.2). Overall exposure was calculated
by multiplying the concentration of MMC by the duration of ex-
posure for each study. We then listed the studies in descending or-
der of MMC exposure to view the overall effect. We excluded one
study that administered the MMC by subconjunctival injection
from this analysis.
When considering the method of 5-FU administration as in Anal-
ysis 1.3, there was no significant effect on the overall outcome
whether the 5-FU was administered by postoperative subconjunc-
tival injections or by the more current method of intraoperative
sponge application (subgroup difference P = 0.93)
Time to failure of functioning trabeculectomy
No trial reported this outcome.
Mean IOP one year from surgery
Seven studies reported mean IOP at 12 months (range 6 to 18
months). On average, people treated with MMC had lower IOP
at one year (mean difference (MD) -3.05 mmHg, 95% CI -4.60
to -1.50) Analysis 1.4. There was inconsistency between trials (I2
= 52%), the MD showing a large range in the studies.
The size of the effect was greater in the high-risk group (MD -
4.18 mmHg, 95% CI -6.73 to -1.64) compared to the low-risk
group (MD -1.72 mmHg, 95% CI -3.28 to -0.16), but the test
for interaction was not statistically significant (P = 0.11).
Postoperative use of antiglaucoma medications
Seven studies reported on the frequency of postoperative use of
antiglaucoma medications. Similar proportions of people treated
with MMC and 5-FU required postoperative medication to con-
trol pressure (RR 1.03, 95%CI 0.57 to 1.85) (Analysis 1.5). There
was no evidence for any difference in effect between high-risk and
low-risk groups (P = 0.88). The low-risk group trials were consis-
tent (I2 = 0%), but we saw different results in the three higher-
risk group trials (I2 = 74%).
Four studies reported the mean number of antiglaucoma med-
ications used. On average, people receiving MMC used fewer
antiglaucoma medications (MD -0.33, 95% CI -0.70 to 0.05),
but the effect was uncertain (CIs include 0.00), and the studies
were inconsistent (I2 = 71%) (Analysis 1.6). The inconsistency in
the trials came from those with a higher risk of failure (I2 = 62%).
However, there was a difference between the trials including par-
ticipants at high risk of failure and those including participants
at low risk of failure with a greater relative effect of MMC in the
higher-risk groups (test for interaction P = 0.06). The main caveat
was that there were only two trials in each group of the analysis.
Reduction in visual acuity
Five studies reported postoperative visual acuity. The proportion
of eyes treated with MMC that lost 2 or more lines of visual acuity
one year after surgery was similar to that of 5-FU, but the CIs were
wide (RR 1.05, 95% CI 0.54 to 2.06) Analysis 1.7.
Quality of life
No trial reported this outcome.
Economic data
No trial reported this outcome.
Adverse outcomes
Bleb leak
Two studies reported bleb leak as a complication encountered fol-
lowing trabeculectomy. Participants receiving MMC were more
likely to have a postoperative bleb leak, although the CI was wide,
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and only two studies reported this outcome (RR 1.22, 95% CI
0.32 to 4.68; I2 = 0%).
Six studies used the term ’wound leak’ rather than ’bleb leak’ in
their assessment of postoperative complications. These studies also
showed, with similar statistics, that participants receiving MMC
were more likely to have a postoperative wound leak than those
receiving 5-FU, although the CI was wide (RR 1.17, 95% CI 0.51
to 2.71; I2 = 0%).
Late hypotony
Five studies reported hypotony post-trabeculectomy. Participants
receiving MMC were more likely to have postoperative hypotony
compared to those participants who received 5-FU, however the
effect was uncertain with wide CIs compatible with no effect or
increased hypotony in the 5-FU group (RR 1.37, 95% CI 0.41 to
4.63; I2 = 0%).
Maculopathy
Four studies reportedmaculopathy following trabeculectomy. Par-
ticipants receiving MMC were more likely to encounter macu-
lopathy postoperatively than those receiving 5-FU, but the effect
was uncertain and CI compatible with no effect or increased mac-
ulopathy in the 5-FU group (RR 1.71, 95% CI 0.35 to 8.33; I2 =
0%).
Cataract
Four studies reported the incidence of postoperative cataract de-
velopment. Participants receiving MMC were more likely to de-
velop cataract than those receiving 5-FU, but again theCIs include
1 (null effect) (RR 1.73, 95% CI 0.65 to 4.61; I2 = 24%).
Shallow anterior chamber
Five studies noted postoperative shallowing of the anterior cham-
ber. Those participants receivingMMCweremore likely to present
with a shallow anterior chamber than those who received 5-FU.
The statistical analysis showed a wide CI (RR 1.22, 95% CI 0.67
to 2.21; I2 = 0%).
Choroidal detachment
Nine studies (549 eyes) reported a choroidal detachment as a post-
operative complication following trabeculectomy. Three studies
(303 eyes) reported the same event as a ’suprachoroidal haemor-
rhage’. The former group of studies found no difference in the
rate of events between those participants who received MMC and
those who received 5-FU (RR 0.86, 95% CI 0.45 to 1.63; I2 =
0%). The latter group of studies favoured those participants who
receivedMMC, although the CI was wide (RR 0.73, 95%CI 0.09
to 5.66; I2 = 18%).
Epitheliopathy
Nine studies (474 eyes) reported this complication following tra-
beculectomy. Those participants who received MMC were less
likely to have an epitheliopathy following surgery than those who
received 5-FU, which is most likely a result of the differences in
the technique of antimetabolite application (RR 0.23, 95% CI
0.11 to 0.47; I2 = 0%).
Tenon’s cyst
Four studies (232 eyes) reported Tenon’s cysts in their postopera-
tive complication analysis. Those participants who receivedMMC
were less likely to have a Tenon’s cyst following surgery, although
the CI was wide (RR 0.94, 95% CI 0.20 to 4.38; I2 = 34%).
Hyphaema
Four studies (250 eyes) documented postoperative hyphaema dur-
ing their follow-up of participants. Participants who received
MMCwere less likely to have a postoperative hyphaema than those
who received 5-FU, which may be a consequence of antimetabo-
lite application differences (RR 0.62, 95% CI 0.42 to 0.91; I2 =
0%).
Endophthalmitis
Four studies (315 eyes) published rates of postoperative endoph-
thalmitis. Participants receiving MMC were more likely to have
endophthalmitis following trabeculectomy than those who re-
ceived 5-FU. The CI was wide (RR 3.89, 95% CI 0.44 to 34.57;
I2 = 0%).
Sensitivity analyses (excluding studies at high risk of
bias)
An interesting feature of these analyses was that the trials at high
risk of bias were also the trials recruiting participants at high risk
of failure. In general, excluding these studies improved the con-
sistency (reduced I2). Although the estimate of effect changed in
these analyses, in general the conclusions (of uncertainty in most
cases) did not.
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Outcome Name All trials Excluding trials at high risk of bias
in 1 or more domains
Analysis 1.1* Failure of functioning trabeculec-
tomy at 1 year
RR 0.54, 95% CI 0.30 to 1.00 RR 1.02, 95% CI 0.50 to 2.04
Analysis 1.4* Mean intraocular pressure at 1 year MD -3.05 mmHg, 95% CI -4.60 to
-1.50
MD -1.72 mmHg, 95% CI -3.28 to
-0.16
Analysis 1.5** Use of postoperative medication at 1
year
RR 1.03, 95% CI 0.57 to 1.85 RR 1.39, 95% CI 0.75 to 2.57
Analysis 1.6* Mean number of postoperative med-
ications at 1 year
MD -0.33, 95% CI -0.70 to 0.05 MD -0.08, 95% CI -0.27 to 0.11
Analysis 1.7** Loss of 2 ormore lines of visual acuity
at 1 year
RR 1.05, 95% CI 0.54 to 2.06 RR 2.00, 95% CI 0.53 to 7.59
CI: confidence interval; MD: mean difference; RR: risk ratio
* The trials at high risk of bias were also the trials of the subgroup
at high risk of failure.
** Two trials with a high risk of failure and one trial with a low
risk of failure were excluded.
D I S C U S S I O N
Summary of main results
We have summarised the results in the Summary of findings for
the main comparison.
We identified 11 trials conducted in the United States, Europe,
Asia and Africa. Five studies enrolled participants at low risk of
trabeculectomy failure, five studies enrolled participants at high
risk of failure, and one study enrolled people with both high and
low risk of failure. None of the included trials enrolled participants
with combined trabeculectomy/cataract surgery.
We considered one study to be at low risk of bias in all domains,
six studies at high risk of bias in one or more domains, and the
remaining four studies at an unclear risk of bias.
Our review showed that the risk of failure of trabeculectomy at
one year after surgery was lower in those participants treated with
MMC compared to those treated with 5-FU. However, the esti-
mate of effect was imprecise, and we cannot exclude important
differences. All 11RCTs contributed to this finding with an overall
mixed study population and varied methodology of antimetabo-
lite application. Although MMC appeared to have a greater suc-
cess and more of an IOP-lowering effect in the higher-risk popula-
tions, we detected no significant difference between the subgroups
of participants at low and high risk of failure in these analyses. We
identified no difference between the visual outcomes of the people
receiving MMC or 5-FU at one year postoperatively nor in the
number of drops used postoperatively.
Evaluation of postoperative complications showed that there was
a higher incidence of epitheliopathy and hyphaema when using
5-FU compared to MMC. However, we found those participants
who received MMC to have more reported bleb leaks, wound
leaks, late hypotony and cataract formation than those who re-
ceived 5-FU. The quality of the evidence was low given that in
general adverse outcomes were rare, and hence estimates of effect
were imprecise. Although there were trends, any real significance
cannot be determined from this review alone.
None of the studies reported quality of life.
Overall completeness and applicability of
evidence
This review is limited owing to the small numbers of and large vari-
ability between studies, for example in participant demographics,
methodology, masking of participants and varied follow-up. Some
of the included studies had only 20 or 30 participants in their
study population, which contrasts with the largest study, which
had 115 participants.
After many years of widespread use of antimetabolite agents, un-
certainty remains about the relative benefits and harms of their
use in trabeculectomy surgery. Newer agents and techniques may
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be developed and evaluated to then eventually take over the role
of antimetabolites.
The majority of studies were carried out in the United States, al-
though we included studies from European, Asian, African and
Middle Eastern countries. Two of the included papers, one in Chi-
nese and one in Italian, were translated. The analysis has taken into
account the risk of failure of each study population and reported
the risk as high or low. This is important when interpreting the
results in a clinical setting in order to reflect the practice popula-
tion. However, results showed a similar trend between high- and
low-risk participants, which perhaps may be due to the inclusion
of poor-quality evidence as discussed.
Quality of the evidence
Overall, we graded the quality of the evidence as low, in most cases
because of risk of bias in the included studies and imprecision
in the estimate of effect. One commonly encountered bias came
from the difficulty in masking participants and surgeons owing
to the different techniques of antimetabolite administration. All
studies included in the review were RCTs, but the variability in
outcome reporting reduced the quality of the evidence for some
outcomes. Each study group reported few complications, which
subsequently led to small numbers being incorporated into the
analysis of complications.
Potential biases in the review process
We identified no obvious bias from the review process.
Agreements and disagreements with other
studies or reviews
Fendi 2013 completed a meta-analysis that showed significantly
higher success rates with the use ofMMC when compared with 5-
FU. This analysis included only five studies with participants who
had recieved previous surgical treatment. Lin 2012 found in an
analysis of eight studies that MMC achieved a significantly lower
postoperative IOP than 5-FU, but MMC and 5-FU were com-
parable in achieving success. Likewise, Abdu 2010 found similar
results to both Lin 2012 and this review with little difference be-
tween the two antimetabolites at achieving success. Abdu 2010
also also found that there was no difference in the mean postoper-
ative IOP between participants who received MMC and partici-
pants who received 5-FU and suggest that further research in this
area would enhance results to determine any true superiority of
either MMC or 5-FU.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provided low-quality evidence that to achieve lower
IOP following trabeculectomy MMCmay be a more effective an-
timetabolite than 5-FU across both high- and low-risk popula-
tions. The risk associated with using either MMC or 5-FU as an
antimetabolite in a routine trabeculectomy was low given the in-
frequent reporting of adverse outcomes.
Implications for research
Antimetabolites are a widely used adjunct in trabeculectomy
surgery to help achieve lower postoperative IOP. However, the use
of these medications may be associated with an increased risk of
sight-threatening complications, predominantly due to the toxic
effects on the conjunctiva and Tenon’s capsule.
Further comparative research on MMC and 5-FU would be re-
quired to enhance reliability and validity of the results shown in
this review. However, the development of newer, safer agents to
control wound healing in glaucoma surgerymay be ofmore benefit
to patients in the longer term. These future agents would require
full evaluation with well-designed trials to become integrated into
clinical practice, particularly through the inclusion of trials with
higher power to detect minimally important clinical differences
and to consider cost and patient-orientated outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Katz 1995
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: USA
Number of participants (eyes): 39 (39)
% women: 67%
Average age: 63 years (range not reported)
Risk of trabeculectomy failure: high
Inclusion criteria:
• requiring trabeculectomy
• history of prior cataract surgery, uveitic glaucoma, neovascular glaucoma, or
previously failed filtering surgery
Exclusion criteria:
• younger than 18 years
• corneal decompensation
Interventions • MMC (20 eyes)
◦ Application: 1 intraoperative application
◦ Dose: 0.5 mg/ml for 5 minutes
◦ Location: between the conjunctiva and the episclera (n = 20 eyes)
• 5-FU (19 eyes)
◦ Application: 10 postoperative injections (daily for 1 week, 3 times in
following week)
◦ Dose: 5 mg
◦ Location: subconjunctival
All surgeries involved a limbus-based conjunctival flap. Scleral flap was closed by 10-
0 nylon sutures. Postoperative topical steroids were used in all participants and tapered
over several weeks. 4 surgeons were involved in the study
Outcomes Postoperative IOP
Number of glaucoma medications used
Change in visual acuity
Follow-up: 1 and 2 years
Notes Date study conducted: May 1990 to March 1991
Conflict of interest: None declared
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated “randomised” but no elaboration of
methods used
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Katz 1995 (Continued)
Allocation concealment (selection bias) Unclear risk No mention of patient concealment of al-
location
Blinding (performance bias and detection
bias)
All outcomes
High risk Surgical method varied between both the
groups, somasking for the surgeon and par-
ticipant was impossible. No mention as to
masking during the follow-up period
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up recorded for all partic-
ipants with recognition of participants lost
to follow-up
Selective reporting (reporting bias) Low risk All intended outcomes were identified and
discussed
Other bias High risk Participants may have received different
postoperative treatment: “The use of an-
tibiotics, cycloplegics, digital massage and
laser suture lysis were left to the discretion
of the surgeon”
Participants received different doses of 5-
FU (average 46.0 mg, +/- 4.9 mg)
Kitazawa 1991
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Japan
Number of participants (eyes): 32 (32)
% women: 38%
Average age: 47 years (range 22 to 81)
Risk of trabeculectomy failure: high
Inclusion criteria:
• failure of medical treatment to control IOP
• 2 or more failed trabeculectomies, neovascular glaucoma, inflammatory
glaucoma, congenital glaucoma, or aphakia
Exclusion criteria: not reported
Interventions • MMC (17 eyes)
◦ Application: 1 intraoperative sponge application
◦ Dose: 0.4 mg/ml for 5 minutes
◦ Location: underneath the conjunctival flap and beneath the scleral flap
• 5-FU (15 eyes)
◦ Application: 10 postoperative injections (each day for 1 week and every
other day for the following week)
◦ Dose: 5 mg
◦ Location: subconjunctival, 90 to 180 degrees away from the surgical site
Following the trabeculectomy, 10-0 monofilament nylon suture was used for the scleral
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Kitazawa 1991 (Continued)
flap, and 10-0 nylon shoelace suture was used for the conjunctival wound closure. Post-
operatively 1.2 mg of dexamethasone was injected subconjunctivally. Topical atropine
and antibiotics were given at the time of surgery. 0.1% betamethasone, 1% atropine
sulfate and 0.3% ofloxacine were used as a standard for all participants postop
Outcomes Mean IOP at 12 months
Category 1 success: IOP controlled without antiglaucoma medication
Category 2 success: IOP controlled with or without topical eye drops
Category 3 success: IOP controlled without any medication or with oral carbonic anhy-
drase inhibitors in addition to topical medication
Success was defined as IOP equal to or less than 20 mmHg without any medication
Follow-up: 7 to 12 months
Notes Date study conducted: December 1989 to November 1990
Conflict of interest: None declared
Funding source: Research grant for Aging and Health from the Ministry of Health and
Welfare, Japan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No clear methods described. Significant
difference between the ages of each group
(P = 0.01)
Allocation concealment (selection bias) Unclear risk Randomly allocated
to intervention groups, but no elaboration
on method used
Blinding (performance bias and detection
bias)
All outcomes
High risk No masking due to nature of 2 techniques
of administration for the interventions, and
no mention of follow-up masking
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statements about attrition or exclusion
made
Selective reporting (reporting bias) Low risk Stated outcome measures were reported
Other bias Low risk The study appears to be free fromother bias
Lamping 1995
Methods Parallel-group randomised controlled trial, 1 or both eyes included
Participants Country: USA
Number of participants (eyes): 74 (80)
% women: 41%
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Lamping 1995 (Continued)
Average age: 71 years (range not reported)
Risk of trabeculectomy failure: high
Inclusion criteria:
• medically uncontrolled glaucoma and posterior lens implants, requiring glaucoma
filtration surgery
Exclusion criteria:
• vitreous in the anterior chamber
Interventions • MMC (40 eyes)
◦ Application: 1 intraoperative sponge application
◦ Dose: 0.4 mg/ml for 2.5 minutes
◦ Location: between the conjunctival and scleral flap
• 5-FU (40 eyes)
◦ Application: 10 postoperative injections (once daily for first 10 days)
◦ Dose: 5 mg
◦ Location: subconjunctival, 180 degrees away from the surgical site
No steroid or antibiotic was used at the time of surgery, but topical prednisolone, to-
bramycin and dexamethasone and atropine were applied postoperatively
Single surgeon
Outcomes Postoperative IOP
Follow-up: week 1, week 2 and months 1, 2, 3, 6, 9 and 12
Notes Date study conducted: Not reported
Conflict of interest: None declared
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Consecutive eyes were selected, no random
sequence generation mentioned
Allocation concealment (selection bias) Unclear risk Randomised allocation to each interven-
tion group, but no elaboration of methods
used
Blinding (performance bias and detection
bias)
All outcomes
High risk No masking due to different methods of
application of the 2 interventions, and no
mention of follow-up masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk Recognition of 1 postop complication that
stopped the use of antimetabolite therapy
in this participant. This participant was not
excluded from the study
Selective reporting (reporting bias) Low risk Stated outcome measures were reported
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Lamping 1995 (Continued)
Other bias Low risk Participants in the 5-FU group received
varied amounts of antimetabolite due to
withholding of treatments if indicated by
complications. 8 participants did not re-
ceive the full dose. This was taken into ac-
count in the data analysis
Mostafaei 2011
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Iran
Number of participants (eyes): 40 (40)
% women: 19%
Average age: 68 years (range 48 to 83)
Risk of trabeculectomy failure: low
Inclusion criteria:
• open-angle glaucoma and uncontrolled IOP with evidence of optic nerve damage
and visual field restriction
Exclusion criteria: none reported
Interventions • MMC (18 eyes)
◦ Application: intraoperative
◦ Dose: 0.02 mg
◦ Location: subconjunctival, 180 degrees away from operating site
• 5-FU (22 eyes)
◦ Application: intraoperative
◦ Dose: 5 mg
◦ Location: subconjunctival
Outcomes Primary outcome of successful surgery defined as an IOP of 6 to 22 mmHg at 6 months
postoperatively
Secondary outcome: complications identified at the 6-month follow-up
IOP using Goldmann applanation
Complications
Follow-up: baseline, 2 weeks postoperatively, 1, 3 and 6 months
Notes Date study conducted: Not reported
Conflict of interest: None declared
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Parallel trial design, but the details not de-
scribed
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Mostafaei 2011 (Continued)
Allocation concealment (selection bias) Unclear risk No report on concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No report on masking
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No report on loss to follow-up.
One reported complication of surgery was
observed but it was notmade clear towhich
study group this participant belonged to
Selective reporting (reporting bias) Low risk All intended outcomes were identified and
reported
Other bias Low risk The study appeared to be free from other
bias
Singh 1997
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Ghana
Number of participants (eyes): 81 (81)
% women: 40%
Average age: 54 years (range not reported)
Risk of trabeculectomy failure: high
Inclusion criteria:
• diagnosis of primary open-angle glaucoma
Exclusion criteria:
• No discussion about previous hypotensive drops. May have been primary
trabeculectomies
Interventions • MMC (44 eyes)
◦ Application: intraoperative sponge
◦ Dose: 0.5 mg/ml for 3.5 minutes
◦ Location: between scleral flap and conjunctiva
• 5-FU (37 eyes)
◦ Application: intraoperative sponge
◦ Dose: 50 mg/ml for 5 minutes
◦ Location: between scleral flap and conjunctiva
Limbal-based conjunctival flaps. Antimetabolite delivered with a sponge and thoroughly
irrigated after required time. 5 surgeons with small variation on technique. Day 1 postop
is when topical gentamycin, prednisolone acetate and atropine therapy started
Outcomes IOP outcomes: < 21 mmHg, < 18 mmHg and < 15 mmHg
Visual acuity
Postoperative complications
Follow-up: Post-operative days 1, 3, 7 and 14 and then average longer term follow up of
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Singh 1997 (Continued)
10 months (+/- 4.41)
Notes Date study conducted: Reported completed in 1995
Conflict of interest: Not reported
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treated decided by the flick of a coin in the
operating theatre
Allocation concealment (selection bias) Low risk Surgeons masked from allocation up until
time of surgery (minimal influence)
Blinding (performance bias and detection
bias)
All outcomes
High risk Surgeons were masked up until time of
surgery but not thereafter. Method of ad-
ministration of treatment similar between
groups. Follow-up team were not masked
as to which antimetabolite the participant
had received
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attempts made to contact missing partici-
pants. No description about the number of
participants lost to follow-up. 81/85 par-
ticipants had at least 3 months’ follow-up
Selective reporting (reporting bias) High risk No stated outcomes in the methods
Other bias Unclear risk Insufficient information
Singh 2000
Methods Parallel-group randomised controlled trial, 1 eye per person
Multicentre
Participants Country: USA
Number of participants (eyes): 108 (108)
% women: not reported
Average age: 66 years (range not reported)
Risk of trabeculectomy failure: low
Inclusion criteria:
• primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary
glaucoma
• poorly controlled IOP despite maximal topical treatment
Exclusion criteria:
• previous conjunctival or intraocular surgery
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Singh 2000 (Continued)
Interventions • MMC (54 eyes)
◦ Application: intraoperative
◦ Dose: 0.4 mg/ml for 2 minutes
◦ Location: not stated
• 5-FU (54 eyes)
◦ Application: intraoperative
◦ Dose: 50 mg/ml for 5 minutes
◦ Location: not stated
Limbal-based conjunctival flaps, closed with 8-0 or 9-0 polyglactin 910 (Vicryl) suture.
Antimetabolite delivered with a sponge and thoroughly irrigated after required time. 18
surgeons were involved in the study. 8 centres
Outcomes This is the preliminary report with plans to extend follow-up time
Main outcome measures were IOP and proportion of participants achieving successful
outcomes, with varying IOP criteria for success (< 21 mmHg, < 18 mmHg, < 15 mmHg
and < 12 mmHg). Post-operative visual acuity, complications and use of IOP-lowing
medications were also included in the follow up data
Notes Date study conducted: December 1996
Conflict of interest: None declared
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed using a mod-
ified Moses-Oakford algorithm, and the
randomisation envelope mailed to the
study co-ordinators at the respective sites
Allocation concealment (selection bias) Low risk Participating surgeons were masked with
regard to antimetabolite use until after par-
ticipant enrolment into the study and writ-
ten informed consent
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Surgeons were masked with regard to an-
timetabolite use until after participant en-
rolment into the study. Participants and fol-
low-up period were not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 participants not included in analysis due
to lack of pre- or intraoperative information
Selective reporting (reporting bias) Low risk Stated outcome measures in the methods
were reported in the results
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Singh 2000 (Continued)
Other bias Low risk The study appears free of other sources of
bias
Sisto 2007
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Italy
Number of participants (eyes): 40 (40)
% women: 35%
Average age: 61 years (range 36 to 75)
Risk of trabeculectomy failure: high
Inclusion criteria:
• neovascular glaucoma
• IOP < 21 mmHg and resistant to medical therapy
• no previous ocular surgery
• best corrected visual acuity > -1.5 logMAR units
Exclusion criteria: not reported
Interventions • MMC (22 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 0.2 mg/ml for 2 minutes
◦ Location: between the sclera and the Tenon’s capsule
• 5-FU (18 eyes)
◦ Application: postoperative injections, commencing on day 7, 2 injections
per week for 2 weeks and then 1 injection per week for 6 weeks
◦ Dose: 0.1 ml of 50 mg/ml
◦ Location: subconjunctival injections near the bleb
Fornix-based conjunctival flaps with single surgeon. No releasable sutures or suture lysis
employed
Outcomes Success defined as IOP < 21 mmHg at final postoperative visit
Qualified success defined if IOP < 21 mmHg with addition of topical treatment. Failure
is uncontrolled IOP equal or above 21 mmHg or vision dropped to no perception of
light
Follow-up: every 3 months in the first year, every 6 months thereafter to maximum 60
months (5 years)
Notes Date study conducted: January 1993 to November 2000
Conflict of interest: Not reported
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Sisto 2007 (Continued)
Random sequence generation (selection
bias)
Low risk 40 consecutive people with neovascular
glaucoma selected.
“All eyes had been assigned with a com-
puter generated randomization code.”
Allocation concealment (selection bias) Unclear risk No statement made
Blinding (performance bias and detection
bias)
All outcomes
Low risk Surgeon not masked due to technique, but
the follow-up staff were masked on collect-
ing postoperative data
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participant data included in analysis.
However, length of follow-up was variable
and no statement was made regarding the
participants lost to follow-up
Selective reporting (reporting bias) Low risk Success criteria defined in the methods
Other bias Unclear risk No attempted power calculations
Uva 1996
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Italy
Number of participants (eyes): 30 (30)
% women: 47%
Average age: 54.1 years (range 45 to 60)
Risk of trabeculectomy failure: low
Inclusion criteria:
• primary open-angle glaucoma uncontrolled with medication or laser therapy
Exclusion criteria:
• previous ocular surgery
• aged 60 years or more
• had been on antiglaucoma medication for less than 3 years
Interventions • MMC (15 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 0.2 mg/ml for 2 minutes
◦ Location: between the sclera and the Tenon’s capsule
• 5-FU (15 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 50 mg/ml was applied for 5 minutes
◦ Location: between the sclera and the Tenon’s capsule
Limbal flap was used that was closed with 10-0 nylon suture. 1% atropine, antibiotic and
steroid was applied at the time of surgery. Conjunctiva was closed with 8-0 polyglactin
synthetic suture
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Uva 1996 (Continued)
Outcomes Postoperative IOP
Visual acuity
Postoperative complications
Follow-up: Mean follow-up 292 days +/- 46.1 days
Notes Date study conducted: Not reported
Conflict of interest: Not reported
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised with a “table of numbers”
technique
Allocation concealment (selection bias) Unclear risk No statement made
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participant masking carried out given same
surgical procedure for both antimetabolite
interventions. Surgeons are presumed to
not be masked given different duration of
antimetabolite application. No mention of
follow-up masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk Commented on all intended outcomes.
Short period of follow-up with all partici-
pants recordedwithin similar follow-up pe-
riod
Selective reporting (reporting bias) Low risk Stated outcome measures in the methods
were reported in the results
Other bias Unclear risk No obvious further bias
WuDunn 2002
Methods Parallel-group randomised controlled trial, 1 or both eyes per person
Participants Country: USA
Number of participants (eyes): 103 (115)
% women: 44%
Average age: 65 years
Risk of trabeculectomy failure: low
Inclusion criteria:
• poorly controlled IOP despite maximal tolerated medical treatment
• primary open-angle glaucoma, pigmentary glaucoma, chronic angle-closure
glaucoma, secondary glaucoma and pseudoexfoliation
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WuDunn 2002 (Continued)
Exclusion criteria:
• previous intraocular surgery
Interventions • MMC (58 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 0.2 mg/ml for 2 minutes
◦ Location: not stated
• 5-FU (57 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 50 mg/ml for 5 minutes
◦ Location: not stated
Limbal-based conjunctival flaps, closed with 8-0 polyglactin 910 (Vicryl) suture. An-
timetabolite was delivered with a cellulose sponge and thoroughly irrigated after required
time. The application was divided into 2 phases to allow surgeon masking through same
time of antimetabolitie/sham application. Corticosteroid, antibiotic ointment and at-
ropine were instilled at the time of surgery. Postoperatively, all eyes received 1% pred-
nisolone acetate, 1% atropine and an antibiotic
Outcomes • Target IOP outcomes < 22, 19, 16, 13 with or without additional topical
treatment were stated, and the IOP reduction had to be greater than 20%.
• Visual acuity
• Glaucoma medication needs
• Complications
• Fail defined as those participants whose preoperative IOP was less than 21 and did
not have a 20% reduction; whose postoperative IOP was above the target level; or if
further surgery to control IOP was required.
• Follow-up: 6 and 12 months
Notes Date study conducted: 1997 to 2001
Conflict of interest: Not reported
Funding source: Research to Prevent Blindness, Inc, New York, New York
NCT00346489
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The assignment schedule was generated in
blocks of 50 (25 per group) by a study co-
ordinator who was not involved in the sur-
gical procedure or clinical care. If the sec-
ond eye of the participant was also enrolled,
it was assigned to the opposite group of the
first eye
Allocation concealment (selection bias) Low risk Group assignment was made randomly on
the day of the surgery by the study co-ordi-
nator and relayed directly to the operating
room circulating nurse who prepared the
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WuDunn 2002 (Continued)
antimetabolite solutions
Blinding (performance bias and detection
bias)
All outcomes
Low risk Only the study co-ordinator and the circu-
lating nurse knew the allocation. The as-
signment code was kept in a locked drawer
in the office of the study coordinator. The
code was broken at 6months postoperative
to allow data analysis
Surgeons were kept masked by using the
same colour solution and the same duration
of sponge application for both intervention
groups (theMMC group had 3-minute ap-
plication of balanced salt solution to equal
the 5-minute 5-FU group in total)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clearly identified participants: 1 partici-
pant in each group failed to reach 6-month
follow-up. By 1 year, the lost to follow-up
were 9 in the 5-FU group and 4 in the
MMC group
Selective reporting (reporting bias) Low risk Stated outcome measures in the methods
were reported in the results
Other bias Low risk The study appears free of other sources of
bias
Xinyu 2001
Methods Parallel-group randomised controlled trial, 1 or both eyes included
Participants Country: China
Number of participants (eyes): 98 (108)
% women: 57%
Average age: 54 years (range 16 to 76)
Risk of trabeculectomy failure: Mixed population: mostly low-risk population, 4 partic-
ipants with previous surgery were termed “high risk”
Inclusion criteria:
Of those in the 5-FU group, 33 eyes were angle-closure glaucoma, 3 open-angle glau-
coma, 2 eyes had glaucoma recurrent following previous control and 2 with previous
glaucoma surgery. Of those in the MMC group, 25 had angle-closure glaucoma, 2 open-
angle, 1 recurrent and 2 with previous glaucoma surgery. In the control group, 33 had
angle-closure glaucoma, 3 open-angle and 2 with recurrence
Exclusion criteria: Not mentioned
Interventions • MMC (30 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 0.2 mg/ml for 5 minutes
◦ Location: not stated
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Xinyu 2001 (Continued)
• 5-FU (40 eyes)
◦ Application: 6 to 8 postoperative injections on alternate days starting on day
3
◦ Dose: 5 mg/ml for 5 minutes
◦ Location: subconjunctival injections, 180 degrees away from the site of
scleral flap
All surgeons used same standard surgical technique.
Control (untreated) group also included. (n = 38)
Outcomes Measure of corneal scarring and corneal staining, postoperative IOP and occurrence of
complications (conjunctivitis, vitreous detachment, hyphaema, corneal epithelial defect,
hypotony and corneal ulcer)
Successful reduction in IOP defined as < 21.06 mmHg.
Follow-up: twice a week for 2 weeks, once a week for the subsequent 4 weeks, and then
1 or 2 times a month thereafter
Notes Date study conducted: May 1995 to October 1999
Conflict of interest: Unable to ascertain with manuscript translation
Funding source: Unable to ascertain with manuscript translation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random division into groups, but no detail
given
Allocation concealment (selection bias) Unclear risk No information of allocation methods
Blinding (performance bias and detection
bias)
All outcomes
High risk Application methods different for all 3
groups, and therefore difficult to mask sur-
geons and participants
Follow-up of participants varied between
3 and 34 months with no clear statement
about minimum length of follow-up
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of attrition/exclusion
Selective reporting (reporting bias) Low risk All intended outcomes were addressed
Other bias Low risk No other obvious bias identified
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Zadok 1995
Methods Parallel-group randomised controlled trial, 1 eye per person
Participants Country: Israel
Number of participants (eyes): 20 (20)
% women: 45%
Average age: 69 years (range not reported)
Risk of trabeculectomy failure: low
Inclusion criteria:
• uncontrolled primary open-angle glaucoma
Exclusion criteria: Not mentioned
Interventions • MMC (10 eyes)
◦ Application: intraoperative sponge application
◦ Dose: 0.2 mg/ml for 5 minutes
◦ Location: between the conjunctiva and episclera
• 5-FU (10 eyes)
◦ Application: up to 7 postoperative injections, once daily in the first week
after surgery
◦ Dose: 5 mg
◦ Location: subconjunctival injections, 180 degrees away from the site of
surgery
Closure of scleral flap by 10-0 nylon sutures. Conjunctiva closed by running suture. All
participants received 1% atropine sulphate twice daily for 4 weeks and dexamethasone
4 times daily, tapered over several weeks
Outcomes IOP < 21 mmHg as a primary outcome with or without antiglaucoma medication
Follow-up: Participants reviewed at 1 week postoperatively, 2 weeks, 1, 2, 3, 6 and 12
months
Notes Date study conducted: Not reported
Conflict of interest: Not reported
Funding source: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of method of selection. Ran-
domised
Allocation concealment (selection bias) Unclear risk No mention of how participants were con-
cealed from their respective allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Surgeons not masked given different ad-
ministration techniques. Follow-up com-
pleted by masked professionals
Incomplete outcome data (attrition bias)
All outcomes
Low risk Evidence from Table 3 (IOP distributions
at 6 and 12 months) that all participants in
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Zadok 1995 (Continued)
study reached full follow-up period
Selective reporting (reporting bias) Low risk All outcomes reported in manuscript
Other bias Low risk No other bias evident
5-FU: 5-Fluorouracil
IOP: intraocular pressure
MMC: mitomycin C
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ashworth 2003 Prospective, non-randomised trial
Dreyer 1995 Not a randomised controlled study. No data on intraocular pressure as an outcome, therefore does not
match inclusion criteria
Li 2001 Prospective, non-randomised trial
Membrey 2000 Retrospective study
Membrey 2001 Case-control; not a randomised controlled study
Oh 1994 Random allocation not mentioned; no reply from authors to request for clarification
Rodriguez-Bermejo 1993 Manuscript not available for review
Characteristics of studies awaiting assessment [ordered by study ID]
Liu 2015
Methods
Participants
Interventions
Outcomes
Notes Awaiting response from authors regarding our query on methods of randomisation
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Susanna 1995
Methods
Participants
Interventions
Outcomes
Notes Unable to locate copy of the report
Yamamoto 1997
Methods
Participants
Interventions
Outcomes
Notes Unable to locate copy of the report
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D A T A A N D A N A L Y S E S
Comparison 1. MMC versus 5-FU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure of functioning
trabeculectomy at one year
11 634 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.30, 1.00]
1.1 Low risk of failure 6 370 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.19, 2.20]
1.2 High risk of failure 5 264 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.22, 1.08]
2 Failure of functioning
trabeculectomy at one year in
descending order of MMC
exposure (dose x duration)
10 594 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.30, 1.00]
3 Failure of functioning
trabeculectomy at one
year depending on 5-FU
administration technique
10 594 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.30, 1.00]
3.1 5-FU by postoperative
injections
6 273 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.27, 1.15]
3.2 5-FU by intraoperative
sponge application
4 321 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.13, 2.08]
4 Intraocular pressure at one year 7 386 Mean Difference (IV, Random, 95% CI) -3.05 [-4.60, -1.50]
4.1 Low risk of failure 3 162 Mean Difference (IV, Random, 95% CI) -1.72 [-3.28, -0.16]
4.2 High risk of failure 4 224 Mean Difference (IV, Random, 95% CI) -4.18 [-6.73, -1.64]
5 Use of postoperative anti-
glaucoma medications at final
follow up
7 426 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.57, 1.85]
5.1 Low risk of failure 4 273 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.60, 2.07]
5.2 High risk of failure 3 153 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.26, 3.76]
6 Mean number of postoperative
anti-glaucoma medications
4 342 Mean Difference (IV, Random, 95% CI) -0.33 [-0.70, 0.05]
6.1 Low risk of failure 2 223 Mean Difference (IV, Random, 95% CI) -0.08 [-0.27, 0.11]
6.2 High risk of failure 2 119 Mean Difference (IV, Random, 95% CI) -0.71 [-1.34, -0.09]
7 Loss of 2 or more lines of Snellen
visual acuity postoperatively
5 328 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.54, 2.06]
7.1 Low risk of failure 2 128 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.53, 7.59]
7.2 High risk of failure 3 200 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.36, 1.80]
8 Postoperative Complications 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Bleb leak 2 154 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.32, 4.68]
8.2 Wound leak 6 391 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.51, 2.71]
8.3 Late hypotony 4 211 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.41, 4.63]
8.4 Maculopathy 4 342 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.35, 8.33]
8.5 Cataract 4 275 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.65, 4.61]
8.6 Shallow anterior chamber 5 311 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.67, 2.21]
8.7 Choroidal detachment 8 494 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.45, 1.63]
8.8 Epitheliopathy 8 419 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.11, 0.47]
8.9 Tenon cyst 3 177 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.20, 4.38]
8.10 Hyphaema 4 250 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.42, 0.91]
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8.11 Suprachoroidal
haemorrhage
3 303 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.09, 5.66]
8.12 Endophthalmitis 4 315 Risk Ratio (M-H, Random, 95% CI) 3.89 [0.44, 34.57]
A D D I T I O N A L T A B L E S
Table 1. Interventions
Study MMC* 5-FU
Dose Duration
(minutes)
Location Intraopera-
tive or post-
operative
Dose Number of
injections
Duration Location
Katz 1995 0.5 mg/ml 5 Between the
conjunctiva
and the epis-
clera
Postopera-
tive
5 mg 10 (daily for
1 week,
3 times fol-
lowing
week)
NA
(injection)
Subcon-
junctival in-
jection
Kitazawa
1991
0.4 mg/ml 5 Between the
conjuncti-
val and scle-
ral flap
Postopera-
tive
5 mg 10 (each day
for 1
week and ev-
ery other day
for the fol-
lowing
week)
NA
(injection)
Subcon-
junctival in-
jections, 90
to 180
degrees away
from the sur-
gical site
Lamping
1995
0.4 mg/ml 2.5 Between the
conjuncti-
val and scle-
ral flap
Postopera-
tive
5 mg 10 (first 10
days)
NA
(injection)
Subcon-
junctival in-
jection, 180
degrees from
operating
site
Mostafaei
2011
0.02 mg not stated Subcon-
junctival in-
jection, 180
degrees away
from operat-
ing site
Intraopera-
tive
5 mg NA Not stated Subcon-
junctival in-
jection
Singh 1997 0.5 mg/ml 3.5 Be-
tween scleral
flap and con-
junctiva
Intraopera-
tive
50 mg/ml NA 5 Be-
tween scleral
flap and con-
junctiva
Singh 2000 0.4 mg/ml 2 Not stated Intraopera-
tive
50 mg/ml NA 5 Not stated
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Table 1. Interventions (Continued)
Sisto 2007 0.2 mg/ml 2 Between the
sclera and
the Tenon’s
capsule
Postopera-
tive
0.1 ml of 50
mg/ml
10 (starting
on day 7,
2 injections
per week for
2 weeks and
then 1 injec-
tion
per week for
6 weeks
NA
(injection)
Subcon-
junctival in-
jections near
the bleb
Uva 1996 0.2 mg/ml 2 Between the
sclera and
the Tenon’s
capsule
Intraopera-
tive
50 mg/ml NA 5 Between the
sclera and
the Tenon’s
capsule
WuDunn
2002
0.2 mg/ml 2 Not stated Intraopera-
tive
50 mg/ml NA 5 Not stated
Xinyu 2001 0.2 mg/ml 5 Not stated Postopera-
tive
5 mg 6 to 8 (al-
ternate days,
starting on
day 3)
NA
(injection)
Subconjunc-
tival, 180
degrees away
from the site
of scleral flap
Zadok 1995 0.2 mg/ml 5 Between the
conjunctiva
and episclera
Postopera-
tive
5 mg (0.5 ml
of 10 mg/ml
solution)
7 (once daily
up to 7 times
in the
first week af-
ter surgery)
NA
(injection)
Subconjunc-
tival, 180de-
grees
from site of
surgery
NA: not applicable
* All MMC only one intraoperative application
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 11, 2015
Date Event Description
10 September 2008 Amended Converted to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not include outomes 1.4, 1.5 and 1.6 in the protocol. Use of postoperative glaucoma medication is a surrogate for partial
trabeculectomy failure and was measured as an outcome in several of the included studies. Visual acuity was another commonly reported
outcome in the included studies, in particular a loss of 2 lines of Snellen visual acuity. We therefore considered it appropriate to include
these two outcomes in our review given their use in the assessment of trabeculectomy outcomes.
No data were available on time to failure as no studies were found to use Kaplan-Meier survival analysis as an outcome measure.
Additionally, only one study commented clearly on non-attendance rates. No data were available on quality-of-life measures. We
therefore did not report outcomes for time to failure, quality of life and non-attendance rate.
Late hypotony, endophthalmitis and choroidal detachment are of clinical interest and significance when concerning trabeculectomy.
We therefore chose these adverse outcomes as priority in the Summary of findings for the main comparison.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Trabeculectomy; Antimetabolites [∗therapeutic use]; Chemotherapy, Adjuvant; Cicatrix [prevention & control]; Fluorouracil
[∗therapeutic use]; Glaucoma [drug therapy; ∗surgery]; Intraocular Pressure [drug effects]; Mitomycin [∗therapeutic use]; Randomized
Controlled Trials as Topic; Risk; Treatment Failure; Wound Healing [∗drug effects]
MeSH check words
Humans
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